1427001-89-5

1427001-89-5 structure

Name: AMY-101
Chemical Name: AMY-101
CAS Number: 1427001-89-5
Molecular Formula: C₈₃H₁₁₇N₂₃O₁₈S₂
Molecular Weight: 1789.11
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2020-06-01 12:45:59
Modify Date: 2024-01-15 12:57:36
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].

Name	AMY-101

Description	AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].
Related Catalog	Signaling Pathways >> Anti-infection >> SARS-CoV Signaling Pathways >> Immunology/Inflammation >> Complement System Research Areas >> Inflammation/Immunology
Target	KD: 0.5 nM (C3)[1].
In Vivo	AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis[1]. AMY-101 can induce a long-lasting anti-inflammatory effect[1]. AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction[1]. Animal Model: Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7 – 15 years old; 5.0 – 7.6 kg body weight)[1]. Dosage: 0.1 mg/site; 50 μL of 2 mg/mL solution. Administration: Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.) Result: Does not cause irritation in healthy gingiva.
References	[1]. Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215. [2]. Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450

Molecular Formula	C₈₃H₁₁₇N₂₃O₁₈S₂
Molecular Weight	1789.11

1427001-89-5	1789738-04-0
1370281-06-3	2219362-20-4
187099-99-6	106566-58-9
1012054-59-9	2564467-03-2
2564467-16-7	912361-26-3
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4
2680816-86-6	849349-65-1